Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24756094 | 0.85 | NR3C2 (0.55) | NR3C2 | |
| SCHEMBL2306170 | 0.83 | L3MBTL1 (0.55) | PIK3C3 | |
| SCHEMBL30442511 | 0.83 | L3MBTL1 (0.55) | PIK3C3 | |
| SCHEMBL6507679 | 0.82 | EGFR (0.54) | EGFRPIK3C3 | |
| SCHEMBL15432242 | 0.80 | JAK2 (0.55) | NR3C2PIK3C3 | |
| SCHEMBL1026072 | 0.80 | FFAR1 (0.47) | NR3C2NPC1RAB9AASIC3 | |
| SCHEMBL17631827 | 0.79 | MKNK1 (0.53) | EGFRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL31408897 | 0.79 | EGFR (0.61) | EGFR | |
| SCHEMBL17377666 | 0.79 | ACVRL1 (0.61) | PIK3C3ACVRL1 | |
| SCHEMBL23445931 | 0.79 | TYK2 (0.56) | NPC1RAB9ASMN1; SMN2ACVRL1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4376845-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023007009-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-02-02 | — | — | WO | disclosed |
| US-10093631-B2 | Bifunctional compounds and use for reducing uric acid levels | ACQUIST LLC (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170197923-A1 | Bifunctional Compounds and Use for Reducing Uric Acid Levels | ACQUIST LLC | 2017-07-13 | — | — | US | disclosed |
| EP-3104861-A1 | BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS | Warrell, Raymond P., Jr. (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015123003-A1 | BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS | WARRELL RAYMOND P (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197923-A1 | Bifunctional Compounds and Use for Reducing Uric Acid Levels | XDH, OAT, ATIC | NR3C2 3325/4885NPC1 752/4885RAB9A 2961/4885 |
| US-10093631-B2 | Bifunctional compounds and use for reducing uric acid levels | XDH, OAT, ATIC | NR3C2 3325/4885NPC1 752/4885RAB9A 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.